^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Published date:
03/16/2021
Excerpt:
c-Met overexpression was associated with a time-to-progression (TTP) after bevacizumab of 3 months (95% CI, 1.5-4.5) compared with a TTP of 7 months (95% CI, 4.6-9.4) in patients with low or no expression of c-Met (p = 0.05).
DOI:
10.1038/s41598-021-85385-1
